An open-label trial of escitalopram in pervasive developmental disorders

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 44, Issue 4, 2005, Pages 343-348

  Owley, Thomas ^a   Walton, Laura ^a   Salt, Jeff ^a   Guter Jr , Stephen J ^a   Winnega, Marrea ^a   Leventhal, Bennett L ^a   Cook Jr , Edwin H ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

Autistic disorder; Drug treatment; Escitalopram; Open label

Indexed keywords

ESCITALOPRAM;

ABERRANT BEHAVIOR CHECKLIST COMMUNITY VERSION; ADOLESCENT; AGE; AGGRESSIVENESS; ARTICLE; AUTISM; BODY WEIGHT; CHILD; CHILD BEHAVIOR; CLINICAL ARTICLE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; DOSE RESPONSE; DRUG EFFECT; FEMALE; HUMAN; INSOMNIA; MALE; MAXIMUM TOLERATED DOSE; OPEN STUDY; PRIORITY JOURNAL; RATING SCALE; SIDE EFFECT; TREATMENT OUTCOME;

EID: 15344341046     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.chi.0000153229.80215.a0     Document Type: Article

References (21)

1. Aman MG, Singh NN, Stewart AW, Field CJ (1985), The Aberrant Behavior Checklist: a behavior rating scale for the assessment of treatment effects. Am J Ment Def 39:485-491
2. American Psychiatric Association (1994), Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington, DC: American Psychiatric Association Press
3. Brodkin ES, McDougle CJ, Naylor ST, Cohen DJ, Price LH (1997), Clomipramine in adults with pervasive developmental disorders: a prospective open-label investigation. J Child Adolesc Psychopharmacol 7: 109-121
4. Carlson GA, Mick E (2003), Drug-induced disinhibition in psychiatrically hospitalized children. J Child Adolesc Psychopharmacol 13:153-163
5. Cook E, Leventhal B (1996), The serotonin system in autism. Curr Opin Pediatr 8:348-354
6. Cook E, Rowlett R, Jaselskis C, Leventhal B (1992), Fluoxetine treatment of patients with autism and mental retardation. J Am Acad Child Adolesc Psychiatry 31:739-745
7. DeLong GR, Teague LA, McSwain Kamran M (1998), Effects of fluoxetine treatment in young children with idiopathic autism. Dev Med Child Neurol 40:551-562
8. Elliott C (1990), DAS Handbook. San Antonio, TX: The Psychological Corporation.
9. Ghaziuddin M, Tsai L, Ghaziuddin N (1991), Fluoxetine in autism with depression. J Am Acad Child Adolesc Psychiatry 30:508-509
10. Gordon C, State R, Nelson J, Hamburger S, Rapoport J (1993), A double-blind comparison of clomipramine, desipramine, and placebo in the treatment of autistic disorder. Arch Gen Psychiatry 50:441-447
11. Hellings JA, Kelley LA, Gabrielli WF, Kilgore E, Shah P (1996), Sertraline response in adults with mental retardation and autistic disorder. J Clin Psychiatry 57:333-336
12. Jaselskis CA, Cook EH, Fletcher KE, Leventhal BL (1992), Clonidine treatment of hyperactive and impulsive children with autistic disorder. J Clin Psychopharmacol 12:322-327
13. King B, Wright D, Handen B et al. (2001), A double-blind, placebo-controlled study of amantadine hydrochloride in the treatment of children with autistic disorder. J Am Acad Child Adolesc Psychiatry 40: 658-665
14. Kroenke K, West SL, Swindle R et al. (2001), Similar effectiveness of paroxetine, fluoxetine, and sertraline in primary care: a randomized trial. JAMA 286:2947-2955
15. Lord C, Risi S, Lambrecht L et al. (2000), The autism diagnostic observation schedule-generic: a standard measure of social and communication deficits associated with the spectrum of autism. J Autism Dev Disord 30:205-223
16. Lord C, Rutter M, Le Couteur A (1994), Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 24:659-685
17. McDougle C, Naylor S, Cohen D, Volkmar F, Heninger G, Price L (1996), A double-blind, placebo-controlled study of fluvoxamine in adults with autistic disorder. Arch Gen Psychiatry 53:1001-1008
18. National Institute of Mental Health (1985), Special feature: rating scales and assessment instruments for use in pediatric psychopharmacology research. Psychopharmacol Bull 21:839
19. Owley T (2002), The pharmacological treatment of autistic spectrum disorders. CNS Spectr 7:663-669
20. Raven J (1947), Coloured Progressive Matrices. Oxford: Oxford Psychologists Press
21. Schain RJ, Freedman DX (1961), Studies on 5-hydroxyindole metabolism in autistic and other mentally retarded children. J Pediatr 58:315-320